Plain-English translation of NCT05099471 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Venetoclax, a newer cancer medication, works better when combined with rituximab (an antibody drug) compared to standard chemotherapy for a rare blood cancer called Waldenström's macroglobulinemia. About 80 newly diagnosed patients will be enrolled. The goal is to see if this medication can produce deeper, longer-lasting responses while being easier to tolerate than current treatments.
Current chemotherapy treatments for this cancer don't work well enough and can be hard on patients, especially older adults. This medication has shown promise in similar blood cancers and in early studies of this disease, so researchers want to test whether combining it with rituximab in a structured 12-month treatment plan could become a better standard of care.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the newer medication plus rituximab or standard chemotherapy. The newer medication group would take pills by mouth for 12 months, with rituximab infusions given once per month starting in month two. The chemotherapy group would receive multiple drugs by mouth and IV infusions over 6 months. You would have regular clinic visits for blood tests, imaging, and monitoring to see how well the treatment works and check for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Germany